U.S. Markets close in 47 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 9,678.80 | -276.70 | -2.78% |
| NASDAQ | 1,798.38 | -64.58 | -3.47% |
| S&P 500 | 1,023.70 | -33.19 | -3.14% |
| Day Low 09:30 AM EDT | 0.58 | |
|---|---|---|
| Day High 10:28 AM EDT | 0.67 |
|
| Range | 0.09 | |
| Volume | 429,599 | |
| 30-Day Avg. Vol. | 3.12 M |
|
| Difference | -86.27% | |
| Market Cap. | 51.54 M | |
| Change | 0 | |
| Shares Out. | 85.9 M | |
| Percent Traded | 0.50% | |
| Revenue (LFY) | 1.38 M | |
| Earnings (TTM) | -99.27 M | |
| Next Earnings | 10/27/2008 |
|
| EPS (TTM) | -1.22 |
| 52-Wk Low 10/6/08 | 0.55 | |
|---|---|---|
| 52-Wk High 5/5/08 | 4.67 |
|
| Range | 4.12 | |
| Prev. Close 10/6/08 | 0.60 | |
| Today's Open | 0.58 | |
| Change | -3.33% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 2.7362 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | 0.00 |
Cell Genesys wants to be the beginning of the end for cancer. The development-stage company is researching biotech treatments for various forms of the disease. Its lead technology is its GVAX immunotherapy ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.416 3/31/08 | -0.29 3/31/08 |
0.126
Beat
|
| Last Quarter | -0.33 6/30/08 | -0.03 6/30/08 |
0.30
Beat
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 16.57 M | 1.38 M |
| Gross Profit | -26.40 M | -104.75 M |
| Operating Income | -13.33 M | -125.15 M |
| Net Income | -2.76 M | -99.27 M |
